GLP-1 receptor agonists have changed the conversation around weight management more dramatically than any class of medication in decades. Tirzepatide and semaglutide, the active compounds behind Mounjaro, Zepbound, Ozempic, and Wegovy, produce weight loss outcomes once achievable only through bariatric surgery. Clinical trials have shown total body weight reductions of 15 to 22 percent, and for millions of people living with obesity or metabolic disease, that is genuinely lif

A Note Before You Begin Weight loss injections have become one of the most searched health topics of the past three years, and for good reason. GLP-1 receptor agonists such as semaglutide and tirzepatide have delivered clinical results that were once considered impossible without surgery: 15 to 22 percent total body weight loss in randomised controlled trials, with meaningful improvements in blood sugar, blood pressure, and cardiovascular risk markers. The surge in demand has